Foghorn Therapeutics, Inc. FHTX 深 滬
等待開盤 01-28 09:30:00 美东时间
5.90
+0.090
+1.55%
華盛通- 最 高5.95
- 今 開5.78
- 成交量 15.26万股
- 最 低 5.73
- 昨 收 5.81
- 總市值 3.34亿
- 52周最高 6.95
- 市盈率 靜 --
- 換手率 0.27%
- 52周最低 2.9448
- 委 比 59.19%
- 總股本 5655.13万
- 歷史最高 28.265
- 量 比 0.74
- 振 幅 3.79%
- 歷史最低 2.70
- 每 手 1
- 風險率 0.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Reported Friday, Foghorn Therapeutics Secures $50M Equity Financing, Advances Oncology Pipeline, And Extends $208.9M Cash Runway Into First Half Of 2028
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026Phase 1 dose-escalation
01-12 16:37
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
BTIG Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $11
BTIG analyst Jeet Mukherjee initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $11.
2025-12-18 20:19
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift to...
2025-12-11 23:17
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
2025-12-05 08:35
Stifel Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12
Stifel analyst Laura Prendergast initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $12.
2025-12-05 00:56
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
<p><p>CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the 8<sup>th</sup> Annual Evercore Healthcare Conference, being held December 2-4, 2025, in Coral Gables, FL. With an initial focus in oncology, Foghorn’s...
2025-11-25 12:00
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
Foghorn Therapeutics Unveils Strategic Advancements with Lilly
Foghorn Therapeutics ( ($FHTX) ) has issued an announcement. In November 2025, ...
2025-11-08 05:59
